Dr. Salim Dhanji reports

ME THERAPEUTICS ANNOUNCES PRIVATE PLACEMENT

ME Therapeutics Holdings Inc. has arranged a non-brokered private placement to raise gross proceeds of up to $500,000 through the issuance of up to 294,117 units at $1.70 per unit. Each unit will comprise one common share and one non-transferable common share purchase warrant, with each warrant being exercisable into one additional share at an exercise price of $2 each for three years from the date of issuance, subject to an acceleration clause, whereby, if the volume-weighted average price of the shares is at or above $3 for 10 consecutive trading days, the company may accelerate the expiry date upon 30 days of notice.

The company intends to use the proceeds of the offering toward advancing research and development, evaluating strategic transactions, pursuing a U.S. listing, marketing, investor relations expenditures, working capital requirements, and other general corporate purposes. The shares and warrants will be subject to a hold period expiring four months and one day from the date of issuance. Insider participation is expected in the offering, although the extent and particulars have not been confirmed. The issuance of securities to insiders of the company pursuant to the offering will be considered related party transactions within the meaning of Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. Subject to investor interest, the company reserves the right to increase the size of the offering to provide for the issuance of up to 588,235 units at $1.70 per unit to raise gross proceeds of up to $1-million. Completion of the offering remains subject to, among other things, compliance with applicable securities laws and the policies of the Canadian Securities Exchange.

About ME Therapeutics Holdings Inc.

ME (Myeloid Enhancement) Therapeutics is a publicly listed biotechnology company based in Vancouver focused on developing novel therapeutics designed to reprogram immune cells in vivo to reshape the tumour microenvironment and to directly recognize and kill cancer cells.

We seek Safe Harbor.